High-Dose-Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian, M.D., Vivian Weinberg, Ph.D.,

Slides:

Advertisements

Similar presentations

High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.

Advertisements

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

A Quantitative Analysis of the Relationship Between Radiation Therapy Use and Travel Time Emma Liu, MM, Pablo Santibáñez, MM, Martin L. Puterman, PhD,

125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy Mira Keyes, MD, Tom Pickles, MD, Alexander Agranovich, MD, Winkle.

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate.

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Jessica L. Conway, MD, Joseph M

COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results.

Non-randomized comparison between definitive concurrent chemoradiotherapy and pre- operative radiotherapy followed by surgery in patients with hypopharyngeal.

The Case for Prostate Brachytherapy in the Affordable Care Act Era

The Role of Diffusion-Weighted Magnetic Resonance Imaging in the Treatment Response Evaluation of Hepatocellular Carcinoma Patients Treated With Radiation.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer Ludmila Katherine Martin, MD,

18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy

Dose-Volume Histogram Predictors of Chronic Gastrointestinal Complications After Radical Hysterectomy and Postoperative Concurrent Nedaplatin-Based Chemoradiation.

Lactate-Base 1H Magnetic Spectroscopy Does Not Predict Response and Outcomes in Patients With Stage IV Head and Neck Squamous Cell Carcinoma Q. Le, A.

Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With.

Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated Michael D. Chuong,

Close or Positive Margins After Mastectomy for DCIS: Pattern of Relapse and Potential Indications for Radiotherapy Afshin Rashtian, M.D., Shawn Iganej,

Ductal Carcinoma In Situ With Microinvasion: Prognostic Implications, Long-Term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, M.D., Bruce.

The impact of ipsilateral breast tumor recurrence on cause specific survival in DCIS patients treated with breast conserving therapy or mastectomy C.

Jerry D Slater, M. D. , Carl J Rossi, M. D. , Les T Yonemoto, M. D

Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate.

A New Model for Imaging and Radiation Therapy Quality Assurance in the National Clinical Trials Network of the National Cancer Institute Thomas J. FitzGerald,

Obituary and Tribute to John “Jack” Francis Fowler, PhD, DSc ( )

Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast.

Lifetime Increased Cancer Risk in Mice Following Exposure to Clinical Proton Beam– Generated Neutrons Leo E. Gerweck, PhD, Peigen Huang, MD, Hsiao-Ming.

Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial Susanne M.

Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials Gustavo Arruda Viani,

Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases Isabelle Thibault, MD, Mikki Campbell,

Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma

International Journal of Radiation Oncology • Biology • Physics

Hendrik Westendorp, MSc, Tonnis T. Nuver, PhD, Carel J

Can interstitial brachytherapy compete with external beam radiotherapy in breast cancer? In response to Drs. Polgár, Major, Strnad, Inoue, and Guedea

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Volume 47, Issue 4, Pages (April 2005)

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K

Prospective Assessment of Patient-Rated Symptoms Following Whole Brain Radiotherapy for Brain Metastases Edward Chow, MBBS, Lori Davis, PhD, Lori Holden,

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis Annemarie T. Fernandes, BA, Eric.

Pain in cancer survivors; filling in the gaps

Thomas M. Pisansky, MD, Douglas G. Gold, MD, PhD, Keith M

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation Filippo Milano, MD, PhD, Brent.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Electronic Updates for JTO Readers

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Linetta B. Koppert, MD, PhD, Albertus N. van Geel, MD, PhD, Titia E

Thymoma—A Clinico-Pathological Long-Term Study with Emphasis on Histology and Adjuvant Radiotherapy Dose Thomas Harnath, MD, Alexander Marx, MD, Philipp.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

George Blumenschein, MD, John V. Heymach, MD, PhD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Efficacy of fiducial marker-based image-guided radiation therapy in prostate tomotherapy and potential dose coverage improvement using a patient positioning.

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Liru He, MD, Pamela K. Allen, PhD, Adam.

Volume 53, Issue 6, Pages (June 2008)

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Pulmonary Resection for Metastases from Colorectal Cancer

Medicaid acceptance among pediatric dermatologists

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Presentation transcript:

High-Dose-Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian, M.D., Vivian Weinberg, Ph.D., Joycelyn L. Speight, M.D., Ph.D., Alexander R. Gottschalk, M.D., Ph.D., Mack Roach, M.D., Katsuto Shinohara, M.D., I.-Chow Hsu, M.D. International Journal of Radiation Oncology • Biology • Physics Volume 82, Issue 1, Pages 222-227 (January 2012) DOI: 10.1016/j.ijrobp.2010.09.021 Copyright © 2012 Terms and Conditions

Fig. 1 Biochemical no-evidence-of-disease (bNED) rate by fractionation at 5-year follow-up. Solid line = 600 cGy × 3 (group 1) and a 5-year bNED rate of 93.5%. Dashed line = 950 cGy × 2 (group 2) and 5-year bNED rate of 87.3% (p = 0.19). International Journal of Radiation Oncology • Biology • Physics 2012 82, 222-227DOI: (10.1016/j.ijrobp.2010.09.021) Copyright © 2012 Terms and Conditions

Fig. 2 Progression-free survival (PFS) rate by fractionation at 5-year follow-up. Solid line = 600 cGy × 3 (group 1) and 5-year PFS rate of 86%. Dashed line = 950 cGy × 2 (group 2) and 5-year PFS rate of 83% (p = 0.53). International Journal of Radiation Oncology • Biology • Physics 2012 82, 222-227DOI: (10.1016/j.ijrobp.2010.09.021) Copyright © 2012 Terms and Conditions

Fig. 3 Progression-free survival (PFS) rate by the number of high-risk features with 600 cGy × 3 HDR boost. Number of failures/total number of patients at 5-year PFS: solid line = none; 3/26 patients; 92%. Dashed line 1 = 11/29 patients; 79%. Dotted lines 2 and 3 = 2/9 patients; 89% (p = 0.13). International Journal of Radiation Oncology • Biology • Physics 2012 82, 222-227DOI: (10.1016/j.ijrobp.2010.09.021) Copyright © 2012 Terms and Conditions

Fig. 4 PFS rate by the number of high-risk features with 950 cGy × 2 HDR boost. Number of failures/total number of patients at 5-year PFS. Solid line = none; 1/23 patients; 95%. Dashed line 1 = 7/44 patients; 81%. Dotted lines 2 and 3 = 6/34 patients; 77% (p = 0.45). International Journal of Radiation Oncology • Biology • Physics 2012 82, 222-227DOI: (10.1016/j.ijrobp.2010.09.021) Copyright © 2012 Terms and Conditions